Von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans

Blood

Volumn 125, Issue 20, 2015, Pages 3153-3163

  Bauer, Alexander T ^a   Suckau, Jan ^a   Frank, Kathrin ^a   Desch, Anna ^a   Goertz, Lukas ^a   Wagner, Andreas H ^a   Hecker, Markus ^a   Goerge, Tobias ^b   Umansky, Ludmila ^c   Beckhove, Philipp ^c   Utikal, Jochen ^a   Gorzelanny, Christian ^a   Diaz Valdes, Nancy ^a,d   Umansky, Viktor ^a   Schneider, Stefan W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b INST OF REPRO MED OF THE UNIV   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FONDAPARINUX; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 6; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN A; TINZAPARIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN BINDING; PROTEIN RET;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CELL ACTIVATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOFLUORESCENCE; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; DISEASE COURSE; DISEASE MODEL; ENZYME ACTIVATION; METABOLISM; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; THROMBOCYTE;

ADAM PROTEINS; ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOTHELIAL CELLS; ENZYME ACTIVATION; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MELANOMA; MICE; MICE, TRANSGENIC; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET AGGREGATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-RET; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON WILLEBRAND FACTOR;

EID: 84929303144     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-595686     Document Type: Article

References (64)

1. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895-904.
2. Wolf MJ, Hoos A, Bauer J, et al. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell. 2012;22(1):91-105.
3. Kerk N, Strozyk EA, Pöppelmann B, Schneider SW. The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells. J Invest Dermatol. 2010;130(9):2259-2268.
4. Desch A, Strozyk EA, Bauer AT, et al. Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin avb5-induced secretion of VEGF-A. Am J Pathol. 2012;181(2):693-705.
5. Goerge T, Barg A, Schnaeker EM, et al. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res. 2006;66(15):7766-7774.
6. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood. 2008;111(11):5271-5281.
7. Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia. 2008;14(suppl 5):11-26.
8. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8(11):1227-1234.
9. Schneider SW, Nuschele S, Wixforth A, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci USA. 2007;104(19):7899-7903.
10. Goerge T, Kleinerüschkamp F, Barg A, et al. Microfluidic reveals generation of platelet-strings on tumor-activated endothelium. Thromb Haemost. 2007;98(2):283-286.
11. Brill A, Fuchs TA, Chauhan AK, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117(4):1400-1407.
12. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014;33(1):231-269.
13. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013;24(1):130-137.
14. Erpenbeck L, Schön MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood. 2010;115(17):3427-3436.
15. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846-1850.
16. Dammacco F, Vacca A, Procaccio P, Ria R, Marech I, Racanelli V. Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. Clin Exp Med. 2013;13(2):85-97.
17. Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013;122(12):2011-2018.
18. Sparsa A, Durox H, Doffoel-Hantz V, et al. High prevalence and risk factors of thromboembolism in stage IV melanoma. J Eur Acad Dermatol Venereol. 2011;25(3):340-344.
19. Kakkar AK, Macbeth F. Antithrombotic therapy and survival in patients with malignant disease. Br J Cancer. 2010;102(suppl 1):S24-S29.
20. Kato M, Takahashi M, Akhand AA, et al. Transgenic mouse model for skin malignant melanoma. Oncogene. 1998;17(14):1885-1888.
21. Umansky V, Abschuetz O, Osen W, et al. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res. 2008;68(22):9451-9458.
22. Zhao F, Falk C, Osen W, Kato M, Schadendorf D, Umansky V. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res. 2009; 15(13):4382-4390.
23. Kimpfler S, Sevko A, Ring S, et al. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol. 2009;183(10):6330-6337.
24. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98(9):2730-2735.
25. Coppo P, Schwarzinger M, Buffet M, et al French Reference Center for Thrombotic Microangiopathies. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS ONE. 2010;5(4):e10208.
26. Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost. 2008;6(7):1233-1235.
27. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104(1):100-106.
28. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788-1795.
29. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS. 2006;114(2):79-102.
30. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307(23):1432-1435.
31. Motto D. Endothelial cells and thrombotic microangiopathy. Semin Nephrol. 2012;32(2):208-214.
32. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589-600.
33. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11-18.
34. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117(11):1449-1459.
35. Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 2013;122(23):3735-3740.
36. Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science. 2009;324(5932):1330-1334.
37. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-494.
38. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001;98(6):1765-1772.
39. Feys HB, Roodt J, Vandeputte N, et al. Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. Blood. 2012;120(17):3611-3614.
40. Barg A, Ossig R, Goerge T, et al. Soluble plasma-derived von Willebrand factor assembles to a haemostatically active filamentous network. Thromb Haemost. 2007;97(4):514-526.
41. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002; 100(12):4033-4039.
42. De Ceunynck K, De Meyer SF, Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood. 2013;121(2):270-277.
43. Moake JL. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol. 2004;41(1):4-14.
44. Chauhan AK, Goerge T, Schneider SW, Wagner DD. Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost. 2007;5(3):583-589.
45. Claus RA, Bockmeyer CL, Budde U, et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost. 2009;101(2):239-247.
46. Meyer C, Sevko A, Ramacher M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA. 2011;108(41):17111-17116.
47. Sevko A, Michels T, Vrohlings M, et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol. 2013;190(5):2464-2471.
48. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423-1437.
49. Siegel-Axel DI, Gawaz M. Platelets and endothelial cells. Semin Thromb Hemost. 2007;33(2):128-135.
50. Ostrovsky L, King AJ, Bond S, et al. A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process. Blood. 1998;91(8):3028-3036.
51. Battinelli EM, Markens BA, Kulenthirarajan RA, Machlus KR, Flaumenhaft R, Italiano JE Jr. Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood. 2014;123(1):101-112.
52. Petri B, Broermann A, Li H, et al. von Willebrand factor promotes leukocyte extravasation. Blood. 2010;116(22):4712-4719.
53. Hillgruber C, Steingraber AK, Poppelmann B, et al. Blocking von Willebrand factor for treatment of cutaneous inflammation. J Invest Dermatol. 2014;134(1):77-86.
54. Nicolaides A, Hull RD, Fareed J; Cardiovascular Disease Educational and Research Trust; European Venous Forum; North American Thrombosis Forum; International Union of Angiology and Union Internationale du Phlebologie. Treatment for patients with cancer. Clin Appl Thromb Hemost. 2013;19(2):206-208.
55. Borsig L. Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb Res. 2010;125(suppl 2):S66-S71.
56. Cleator JH, Zhu WQ, Vaughan DE, Hamm HE. Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP. Blood. 2006;107(7):2736-2744.
57. Norrby K, Nordenhem A. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS. 2010;118(12):949-957.
58. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13(1):9-22.
59. Schuster C, Eikesdal HP, Puntervoll H, et al. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS ONE. 2012;7(6):e38364.
60. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277-2285.
61. Yang Y, Zhang Y, Cao Z, et al. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci USA. 2013;110(29):12018-12023.
62. Bockmeyer CL, Claus RA, Budde U, et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica. 2008;93(1):137-140.
63. Pappelbaum KI, Gorzelanny C, Grässle S, et al. Ultralarge von Willebrand factor fibers mediate luminal Staphylococcus aureus adhesion to an intact endothelial cell layer under shear stress. Circulation. 2013;128(1):50-59.
64. Bridges DJ, Bunn J, van Mourik JA, et al. Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings. Blood. 2010;115(7):1472-1474.